TKNO at a glance
The past year
Chart+84.1% $7.88, close Nov 18
- From the highest close
- −15.5%
- Vs the 200-day average
- +51.5%
Short interest
History1.5M shares
- Of shares outstanding
- 2.45%
- Since the last report
- −6.7%
- Days to cover
- 1.4 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
TKNO price history
Loading recent earnings…
Investment thesis
What must happen next
Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow.StrengtheningMateriality: High
gross_profit increased from 7,231,000 (FY2024) to 13,441,000 (FY2025), reversing the 2024 weakness. If true, gross margin expansion will fund operating leverage and support valuation; if false, commoditization or easy supplier substitution will compress margins and revenue economics.
Watch: Large incumbents (e.g., Thermo Fisher / Merck Millipore) win marquee supplier agreements that shift enterprise spend away from midsized specialty suppliers.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
gross_profit increased from 7,231,000 (FY2024) to 13,441,000 (FY2025), reversing the 2024 weakness.
Open source ↗Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization.HoldingMateriality: High
revenue rose to 40,520,000 in FY2025 from 37,745,000 in FY2024 (positive sequential trend). Faster revenue growth reduces the likelihood that the high multiple overhangs the stock and provides the volume base needed for operating leverage; if growth stalls the premium P/S cannot be justified.
Watch: Macro R&D spending cuts or biotech funding downturns that reduce demand for reagents.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue rose to 40,520,000 in FY2025 from 37,745,000 in FY2024 (positive sequential trend).
Open source ↗As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even.HoldingMateriality: Medium
operating_income improved from (35,563,000) in FY2023 to (26,146,000) in FY2024 to (16,976,000) in FY2025 — consistent, multi‑year improvement. Turning improving gross profit into positive operating income is the step that converts product economics into sustainable free cash flow and validates the valuation; failing to do so means the company remains dependent on financing.
Watch: Continued high SG&A or R&D spending to chase growth that offsets gross margin gains.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_income improved from (35,563,000) in FY2023 to (26,146,000) in FY2024 to (16,976,000) in FY2025 — consistent, multi‑year improvement.
Open source ↗Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value.WeakeningMateriality: Medium
cash declined from 42,236,000 (FY2023) to 3,708,000 (FY2024) and was 5,912,000 at FY2025 year‑end. A financing event would dilute shareholders and reset expectations; achieving self‑funding would validate the path to durable value.
Watch: Access to capital markets or debt on reasonable terms that avoids heavy dilution.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
cash declined from 42,236,000 (FY2023) to 3,708,000 (FY2024) and was 5,912,000 at FY2025 year‑end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow. If true, gross margin expansion will fund operating leverage and support valuation; if false, commoditization or easy supplier substitution will compress margins and revenue economics.
Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization. Faster revenue growth reduces the likelihood that the high multiple overhangs the stock and provides the volume base needed for operating leverage; if growth stalls the premium P/S cannot be justified.
As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even. Turning improving gross profit into positive operating income is the step that converts product economics into sustainable free cash flow and validates the valuation; failing to do so means the company remains dependent on financing.
Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value. A financing event would dilute shareholders and reset expectations; achieving self‑funding would validate the path to durable value.
All standing thesis claims
Original report summary
Teknova monetizes proprietary, short‑turnaround reagent manufacturing to serve >3,000 life‑science customers, translating process-driven quality and customization into durable pricing power and margin recovery as volumes scale.
Bull case and bear case
Bull case and bear case for Alpha Teknova
Where the evidence on Alpha Teknova disagrees: Mixed on the latest evidence (Nov 10, 2026). Of its 4 thesis points, 1 strengthening, 2 holding and 1 weakening.
Bull case: what the evidence supports
Teknova's proprietary, configurable manufacturing processes and fast turnaround create customer stickiness and allow premium pricing, which supports higher gross profit and gross margins as volumes grow.
Commercial adoption of Teknova's Clinical Solutions and scale‑up of custom products will accelerate revenue growth beyond its recent low‑double‑digit pace as more development programs move to commercialization.
As gross margin recovers, Teknova can achieve operating leverage (through fixed‑cost absorption and scaling of higher‑margin Clinical Solutions) and materially reduce operating losses toward break‑even.
Bear case: what the evidence questions
Given low reported cash relative to operating cash burn, Teknova must either achieve rapid positive operating cash flow or raise external capital; failure to do either will force dilutive financing and impair per‑share value.
Company research
Research on Alpha Teknova
- Reporting · Alpha Teknova, Inc. (NASDAQ: TKNO) Adds Regulatory Support for PluriFreeze
A Drug Master File can simplify customer filings, but FDA does not approve DMFs and Teknova has not disclosed PluriFreeze revenue.
Thesis-Break Engine
What has broken in Alpha Teknova’s thesis
Each break OptimistFi flagged on Alpha Teknova, dated — with what has historically followed the same kind of break across the market, not a forecast for Alpha Teknova.
- Operating-margin compression
Early warning
The break condition read on the trailing twelve months through Alpha Teknova’s latest quarterly report, ahead of the annual figure it is written on.
- Operating-margin compression, trailing 12 months
Across all companies, this kind of early warning has happened 2,641 times before. Those stocks trailed the market by a median of 1% over the next six months, and 36% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Alpha Teknova filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Alpha Teknova filed an SEC 8-K on 2026-10-21: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Alpha Teknova filed an SEC 8-K on 2026-08-05: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Large incumbents (e.g., Thermo Fisher / Merck Millipore) win marquee supplier agreements that shift enterprise spend away from midsized specialty suppliers.
- Macro R&D spending cuts or biotech funding downturns that reduce demand for reagents.
- Continued high SG&A or R&D spending to chase growth that offsets gross margin gains.
- Access to capital markets or debt on reasonable terms that avoids heavy dilution.
TKNO news
Loading headlines…
Financial statements
TKNO income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
TKNO: quick answers
- When does Alpha Teknova (TKNO) report earnings next?
- Alpha Teknova's next results are projected for February 25, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
- What is TKNO's short interest?
- As of October 30, 2026, 1.5M TKNO shares were sold short, 2.45% of its shares outstanding, down 6.7% from the count before. At the stock's average daily volume that is 1.4 days to cover. FINRA publishes the count twice a month. TKNO short interest history

